Ames MPF, Ames MPF Penta I, Ames II

• Sini Flückiger-Isler, Markus Kamber; Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames preincubation assay on agar plates by use of equivocal to weakly positive test compounds; Mutation Research 747 (2012) 36–45
• Markus Kamber, Sini Flueckiger-Isler, Gunter Engelhardt, Rudolf Jaeckh and Errol Zeiger; Comparison of the Ames II and traditional Ames test responses with respect to mutagenicity, strain specificities, need for metabolism and correlation with rodent carcinogenicity; Mutagenesis vol. 24 no. 4 pp. 359–366, 2009 doi:10.1093/mutage/gep017
• F. Aktienzar; Evaluation of a Battery of Early Genotoxicity Assays to Predict Regulatory Testing, UCB Pharma, ADMET meeting, Brussels 22, 23 Jan 2009
• Larry R. Williams; Toxicologic characterization of a novel explosive, triaminoguanidinium-1-methyl-5-nitriminotetrazolate (TAG-MNT), in female rats and in vitro assays; Journal of Toxicology and Environmental Health Sciences Vol. 3(3) pp. 80-94, March 2011
• Agata Skrzypczak, Grzegorz Nałęcz; Cytotoxicity assessment approach in short-term bacterial genotoxicity assays, Poster Setac 2013
• P.A. Escobar et al.; Bacterial mutagenicity screening in the pharmaceutical industry; Mutat. Res. 752(2) (2013) 99-118
• P.A. Escobar: Corrigendum to ‘‘Bacterial mutagenicity screening in the pharmaceutical industry’’ Mutation Research 753 (2013) 155
• Gisela de Aragao Umbuzeiro; Comparison of the Salmonella/Microsome Microsuspension Assay with the newMicroplate Fluctuation Protocol for Testing theMutagenicity of Environmental Samples; Environmental and Molecular Mutagenesis 51:31-38 (2010)
• K Braun; Automation of the Ames II Assay: High Through-put screening of mutagenic substances; Aventis Pharma Deutschland GmbH, DI & A, Lead Optimization, Drug Safety Evaluation MipTec ICAR (2001).
• S Flückiger-Isler, M Baumeister, K Braun, V Gervais, N Hasler-Nguyen, R Reimann, J van Gompel, H-G Wunderlich, G Engelhardt; Assessment of the performance of the Ames II assay: A collaborative study with 19 coded compounds; Mutation Res (2004) 558, 181-197.
• M Crook; Automation of the Ames II toxicology test; MipTec-ICAR (2000), P07.
• P Gee, CH Sommers, AS Melick, XM Gidrol, MD Todd, RB Burris, ME Nelson, RC Klemm, E Zeiger; Comparison of responses of base-specific Salmonella tester strains with the traditional strains for identifying mutagens: The results of a validation study; Mutation Res (1998) 412, 115-130.
• WW Piegorsch, SJ Simmons, BH Margolin, E Zeiger, XM Gidrol, P Gee; Statistical modeling and analyses of a base-specific Salmonella mutagenicity assay; Mutation Res (2000) 467, 11-19.
  
• G Engelhardt, E Jacob, R Jäckh; Ames II assay: Results of a validation study; Naunyn-Schmiedeberg’s Arch Pharmacol (1999) 359, 179.
• V Gervais, D Bijot, N Claude; Assessment of a screening experience with the Ames II test and future prospects; European Environmental Mutagen Society Annual Meeting: From Hazard to risk, Aberdeen Scotland (UK) (2003) P120.
• S. Flückiger-Isler, Markus Kamber; The Ames MPF® 98/100 Assay: Novel Mutagenicity Testing in Liquid Microplate Format using S.typhimurium TA98 and TA100 (2006)
• S. Flückiger-Isler, Markus Kamber; The Ames MPF® 98/100 Assay: Novel Mutagenicity Testing in Liquid Microplate Format using S.typhimurium TA98, TA100, TA1535 and TA1537 (2007)
• P Gee, DM Maron, BN Ames; Detection and classification of mutagens: A set of base-specific Salmonella tester strains; Proc Nat Acad Sci USA (1994) 91, 11606-11610.